Stada And Xbrane Receive MHRA Nod For Ranibizumab

Ximluci Biosimilar Rival To Lucentis Will Be Launched ‘During 2023’

The MHRA has approved Ximluci in Great Britain • Source: Shutterstock

More from Products

More from Generics Bulletin